ACUTE STROKE TREATMENT DEVICE

Clotbust ERCerevast has developed a first-in-class Ultrasonic Headframe System called the Clotbust ER as a treatment for ischemic stroke.  This device delivers therapeutic ultrasound energy to the region of the occluded vessel in the brain as a treatment for ischemic stroke when used in combination with  standard intravenous thrombolytic drug therapy.

EASE OF USE AND RAPID DEPLOYMENT IN THE ER

erFollowing standard of care imaging to determine the location of the thrombus, the appropriate transducer array is selected to direct therapeutic ultrasound to the specific region of the brain in where the vessel occlusion is located.  The transducers do not need to be aimed as the device contains external features, which self-align the transducers based on known anthropometric landmarks on the skull.  Proprietary software controls the ultrasound parameters, which in turn allows the device to deliver therapeutic levels of ultrasound energy necessary to achieve acoustic streaming and enhanced clot lysis within the occluded vessel of the brain without the need for a trained sonographer or ultrasound technician. By incorporating these operator independent features into the device, emergency room personnel, paramedics and other health care professionals can quickly and safely deploy this technology in the emergency room setting.

INTEGRATES INTO CURRENT STANDARD OF CARE FOR ACUTE STROKE TREATMENT

IV thrombolysis therapy and mechanical thrombectomy remain the two primary treatment options for acute stroke patients. For those hospitals that are not equipped to perform thrombectomy, Clotbust ER therapy can be administered as a front-line adjunct to conventional IV thrombolytic therapy.  In addition, Clotbust ER therapy can be administered to those patients that are determined to be candidates for thrombectomy while being prepped or during transfer to primary or comprehensive stroke hospitals for this procedure to increase the odds of early recanalization and improved functional outcomes.

By employing this approach, Cerevast’s Clotbust ER therapy can serve as an adjunct to existing standard-of-care treatments while simultaneously reducing the technical challenges associated with the administration of transcranial ultrasound to enable broad market uptake within the stroke treatment community.